Zydus Cadila, one of the leading pharmaceutical companies, has received tentative approval from the USFDA to market Glipizide extended release tablets in the strengths of 2.5 mg, and 10 mg. The drug falls in the ant-diabetic segment.

The estimated sales in 2014 for Glipizide R tablets are USD 90.1 million, as per IMS.

The group now has 97 approvals and has so far filed 249 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 25.55, or 1.98%, to trade at Rs 1,312.85. The total volume of shares traded was 33,197 at the BSE (12.02 p.m., Tuesday).